探戈治疗 TNGX
$21.50 +$0.63 (+3.02%)
休市 · Nov 8, 5:30 am ET · 最新盘后价 $21.50 0.00%
开盘$20.74
昨收$20.87
当日区间$20.74 – $22.11
成交量2.13M
市值$3.63B
市盈率（TTM）–
股息率–
TNGX 相关新闻
匹配 Tango Therapeutics 或代码 TNGX 的头条新闻，按最新排序。
- Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35
- CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46
- H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68 正面
- Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40
- Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35 正面
- Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)
- Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39 正面
- J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46
- A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42
- CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46 正面
- Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60
- Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 正面
- CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42
- H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66
- A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66
暂无评论——快来第一个聊聊 TNGX。
登录后参与讨论。